Drug-Facilitated Weight Loss Benefits Cardiometabolic Status
Weight loss, including phentermine/topiramate-induced, linked to reductions in lipids, blood pressure
FRIDAY, April 12 (HealthDay News) -- Obese and overweight patients with dyslipidemia or hypertension treated with phentermine and topiramate extended-release (PHEN/TPM ER) for weight loss had significant improvements in cardiovascular disease risk factors, according to research published in the April 15 issue of The American Journal of Cardiology.
Michael H. Davidson, M.D., of University of Chicago, and colleagues conducted a subgroup analysis of subjects with either hyperlipidemia or hypertension who participated in the CONQUER study, a randomized, double-blind, placebo-controlled, multi-center study, to determine changes in cardiometabolic risk factors in subjects treated with PHEN/TPM ER.
According to the researchers, in a subgroup of 647 patients with dyslipidemia or hypertension, treatment with either low or high dose of PHEN/TPM ER resulted in significantly greater percentage weight loss than patients treated with placebo. Independent of treatments, significantly greater reductions in triglycerides (-14.5 percent to -39.8 percent) and non-high-density lipoprotein cholesterol (-9.4 percent to -14.8 percent) were observed in patients with dyslipidemia who lost ≥ 5 percent of their weight than those who lost < 5 percent of their baseline weight. Patients with hypertension who lost ≥ 5 percent of their weight also had significantly greater reductions in systolic blood pressure (-7.5 to -11.8 mm Hg).
"The dose-related weight loss induced by PHEN/TPM ER, the associated beneficial effects on cardiometabolic risk factors, and the reductions in medication use indicate that PHEN/TPM ER treatment may be an important addition to the therapeutic armamentarium for obese and overweight patients with comorbidities such as hypertension and dyslipidemia," the authors write.
The study was supported by VIVUS, Inc., Mountain View, California and several authors disclosed financial relationships with pharmaceutical and biotechnology companies.